Trials / Recruiting
RecruitingNCT06753838
Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The PFA (platelet function analysis) test is prescribed for the exploration of primary hemostasis and the study of platelet-willebrand factor interaction. It is performed using citrated blood, with technical difficulties and frequent alarms that may be linked to the choice of anticoagulant (citrate). It is proposed to compare the results obtained with a conventional citrate tube and a BAPA tube, which is an anticoagulant used in clinical research and which blocks coagulation by another mechanism that would have less impact on blood platelets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Sampling of 3 additional BAPA tubes | the 3 additional tubes will be taken at the same time as the blood sample taken for the routine PFA test |
Timeline
- Start date
- 2025-01-21
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-12-31
- Last updated
- 2025-09-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06753838. Inclusion in this directory is not an endorsement.